FIELD: calcium complexes.
SUBSTANCE: invention relates to a calcium complex of the formula [Ca(HAEE)]mXn, where Ca is a doubly charged calcium (II) cation, m = 1 for singly and doubly charged anions, m = 3 for triply charged anions, HAEE is a synthetic peptide acetylated at N -terminus and amidated at the C-terminus, with the amino acid sequence His-Ala-Glu-Glu, X is a pharmaceutically acceptable anion, n = 1 for doubly charged anions, n = 2 for singly and triply charged anions. A method for producing a calcium complex, a pharmaceutical composition based on it and its use are also proposed.
EFFECT: proposed calcium complex is used to treat neurodegenerative diseases.
28 cl, 7 dwg, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| HAEE PEPTIDE MAGNESIUM COMPLEX FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | 2022 |
|
RU2784746C1 |
| HAEE PEPTIDE ZINC COMPLEX FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | 2022 |
|
RU2784319C1 |
| HAEE PEPTIDE COPPER COMPLEX FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | 2022 |
|
RU2784732C1 |
| SODIUM SALT OF HAEE PEPTIDE FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | 2022 |
|
RU2784326C1 |
| AMMONIUM SALT OF HAEE PEPTIDE FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | 2022 |
|
RU2784249C1 |
| POTASSIUM SALT OF HAEE PEPTIDE FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | 2022 |
|
RU2784425C1 |
| METHOD FOR TREATING NEURODEGENERATIVE DISEASES | 2021 |
|
RU2777871C1 |
| PHARMACEUTICAL COMPOSITION BASED ON HAEE PEPTIDE FOR TREATING NEURODEGENERATIVE DISEASES | 2019 |
|
RU2709539C1 |
| HAEE SYNTHETIC TETRAPEPTIDE AND DERIVATIVES THEREOF INTENDED FOR HUMAN NEURON FUNCTION RECOVERY | 2023 |
|
RU2822603C1 |
| SYNTHETIC TETRAPEPTIDE HAEE AND DERIVATIVES THEREOF INTENDED FOR PROTECTION OF HUMAN NEURON FUNCTION | 2023 |
|
RU2822602C1 |
